• 教育部部定教授

• 慈濟大學醫學系教授

• 慈濟大學醫學系核子醫學科主任

• 花蓮慈濟醫院核子醫學科副主任

• Best abstract award from Taiwan, Annual Congress of the Societyof Nuclear Medicine and Molecular Imaging, 2016 (San Diego, USA)
• Poster award, Clinical Oncology, Annual Congress of the Societyof Nuclear Medicine and Molecular Imaging, 2016 (San Diego, USA)
• Presentation selected for Highlight Talking, Annual Congress of the Societyof Nuclear Medicine and Molecular Imaging, 2016 (San Diego, USA)

• 林口長庚醫院核子醫學科科主任
• 基隆長庚醫院核子醫學科科主任
• 嘉義長庚醫院核子醫學科科主任
• 林口長庚醫院核子醫學科主治醫師
• 核子醫學科專科醫師證書(Nuclear medicine)
• 中華民國核醫學學會(Society of Nuclear Medicine – Taiwan)
• 台灣醫學會(Formosan Medical Association)

個人網站:https://www.researchgate.net/profile/Sheng-Chieh-Chan

研究

• 國家科學及技術委員會研究計畫（NSTC）：107-2314-B-182A-064；108-2314-B-182A-021；109-2314-B-303-009；110-2314-B-303-014；111-2314-B-303-006；115-2314-B-303-009。

  ResearchGate: https://www.researchgate.net/profile/Sheng-Chieh-Chan?ev=hdr_xprf

近年期刊論文(Journal publication)

1. A scoring model based on lymph node-to-primary tumor standardized uptake value ratio aids in classifying neck nodal metastasis risk in patients with head and neck cancer treated by surgery. Nucl Med Commun. 2026 Jul 7. Online ahead of print. (Corresponding author)
2. Prognostic utility of 18F-FDG PET/MRI with intravoxel incoherent motion imaging in nasopharyngeal carcinoma. Eur J Nucl Med Mol Imaging. 2025 Dec;53(1):338-349. (First author)
3. Investigation of the diagnostic and prognostic impact of posttreatment fluorine-18 fluorodeoxyglucose PET/computed tomography on M0 esophageal cancer. Nucl Med Commun. 2025;46(9):816-823. (Corresponding author)
4. 18F-FET PET/CT can aid in diagnosing patients with indeterminate MRI findings for brain tumors: a prospective study. Ann Nucl Med. 2025 Apr;39(4):342-352. (First author)
5. Genomic and Glycolytic Entropy Are Reliable Radiogenomic Heterogeneity Biomarkers for Non-Small Cell Lung Cancer. Int J Mol Sci. 2023;24(4):3988.
6. Baseline and interim [18F]FDG-PET/MRI to assess treatment response and survival in patients with M0 esophageal squamous cell carcinoma treated by curative-intent therapy. Cancer Imaging. 2023;23:109. (Corresponding author)
7. Prospective Investigation of 18FDG-PET/MRI with Intravoxel Incoherent Motion Diffusion-Weighted Imaging to Assess Survival in Patients with Oropharyngeal or Hypopharyngeal Carcinoma. Cancers (Basel). 2022; 14(24):6104. (first author)
8. Radiomics for Predicting Survival in Patients with Locally Advanced Hypopharyngeal Cancer Treated with Concurrent Chemoradiotherapy. Cancers (Basel). 2022;14(24):6119.
9. Association of early changes of circulating cancer stem-like cells with survival among patients with metastatic breast cancer. Ther Adv Med Oncol. 2022 Jul 15;14:17588359221110182.
10. Tumor glycolytic heterogeneity improves detection of regional nodal metastasis in patients with lung adenocarcinoma. Ann Nucl Med. 2022 Mar;36(3):256-266.
11. 18F-Fluorodeoxyglucose PET/CT for Early Prediction of Outcomes in Patients with Advanced Lung Adenocarcinomas and EGFR Mutations Treated with First-Line EGFR-TKIs. Cancers (Basel). 2022, 14(6), 1507.
12. Prognostic Value of Combing Primary Tumor and Nodal Glycolytic-Volumetric Parameters of 18F-FDG PET in Patients with Non-Small Cell Lung Cancer and Regional Lymph Node Metastasis. Diagnostics (Basel). 2021 Jun 9;11(6):1065. (Corresponding author)
13. Prospective comparison of early interim 18F-FDG-PET with 18F-FLT-PET for predicting treatment response and survival in metastatic breast cancer. BMC Cancer. 2021;21(1):908. (Corresponding author)
14. Predicting the risk of interval distant metastases in patients with esophageal squamous cell carcinoma undergoing chemoradiotherapy. J Formos Med Assoc. 2022 Feb;121(2):539-545.
15. Combing MRI Perfusion and 18F-FDG PET/CT Metabolic Biomarkers Helps Predict Survival in Advanced Nasopharyngeal Carcinoma: A Prospective Multimodal Imaging Study. Cancers (Basel). 2021 Mar 26;13(7):1550. (First author).
16. Prognostic Value of Baseline Radiomic Features of 18F-FDG PET in Patients with Diffuse Large B-Cell Lymphoma. Diagnostics (Basel). 2020 Dec 29;11(1):36.
17. Incorporating radiomic feature of pretreatment 18F-FDG PET improves survival stratification in patients with EGFR-mutated lung adenocarcinoma. PLoS One. 2020 Dec 28;15(12):e0244502. (Corresponding author).
18. Preoperative F-18 fluorocholine PET/CT for the detection of hyperfunctioning parathyroid glands in patients with secondary or tertiary hyperparathyroidism: comparison with Tc-99m sestamibi scan and neck ultrasound. Ann Nucl Med. 2020;34:527-537. (Corresponding author)
19. Multiparametric PET/MRI in nasopharyngeal carcinoma: correlations between MRI functional parameters and 18F-FDG PET imaging biomarkers and their predictive value for treatment failure. Tzu Chi Med J. 2020;33:61-69. (First author)
20. Pretreatment 18F-FDG PET/CT texture parameters provide complementary information to Epstein-Barr virus DNA titers in patients with metastatic nasopharyngeal carcinoma. Oral Oncol. 2020;104:104628.
21. Prognostic Value of Lymph Node-To-Primary Tumor Standardized Uptake Value Ratio in Esophageal Squamous Cell Carcinoma Treated With Definitive Chemoradiotherapy. Cancers (Basel). 2020;12:607.
22. Radiation safety assessment of caregivers of thyroid cancer patients treated with 131I in Taiwan. Radiation Physics and Chemistry. 2020;172:108781.
23. Comparison of 18F-FDG PET/MRI, MRI, and 18F-FDG PET/CT for the detection of synchronous cancers and distant metastases in patients with oropharyngeal and hypopharyngeal squamous cell carcinoma. Eur J Nucl Med Mol Imaging. 2020;47:94-104. (Co-first author)
24. Baseline circulating stem-like cells predict survival in patients with metastatic breast cancer. BMC Cancer. 2019;19:1167.
25. Textural features on 18F-FDG PET/CT and dynamic contrast-enhanced MR imaging for predicting treatment response and survival of patients with hypopharyngeal carcinoma. Medicine (Baltimore). 2019;98:e16608. (Co-first author)
26. Combining the radiomic features and traditional parameters of 18F-FDG PET with clinical profiles to improve prognostic stratification in patients with esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy and surgery. Ann Nucl Med. 2019;33:657-670. (Corresponding author)
27. Value of early evaluation of treatment response using 18F-FDG PET/CT parameters and the Epstein-Barr virus DNA load for prediction of outcome in patients with primary nasopharyngeal carcinoma. Eur J Nucl Med Mol Imaging. 2019;46:650-660. (Corresponding author)
28. Clinical utility of simultaneous whole-body 18F-FDG PET/MRI as a single-step imaging modality in the staging of primary nasopharyngeal carcinoma. Eur J Nucl Med Mol Imaging. 2018;45:1297-1308. (First author)

近年國際會議發表

1. The utility of multiparametric imaging with 18F-FDG PET and MRI in predicting survival outcome of patients with nasopharyngeal carcinoma. Annual Congress of the European Association of Nuclear Medicine, 2021.
2. Dynamic 18F-FET PET aids in treatment planning of patients with brain tumor: a prospective study in Taiwan. Annual Congress of the European Association of Nuclear Medicine, 2022.
3. Baseline and interim 18FDG-PET/MRI to assess treatment response and survival in patients with esophageal squamous cell carcinoma treated by curative-intent therapy. Annual Congress of the European Association of Nuclear Medicine, 2022.
4. Surveillance 18F-FDG PET/CT in predicting the prognosis of esophageal cancer patients. Annual Congress of the European Association of Nuclear Medicine, 2023.
5. Tumor Volume Auto-delineation and Survival Prediction for Head and Neck Cancer Patients Using Deep Learning on PET/CT Images. Annual Congress of the European Association of Nuclear Medicine, 2024.
6. A Predictive Model Based on Lymph Node-to-Primary Tumor SUV Ratio Accurately Classifies Neck Nodal Malignancy Risk and Guides Neck Dissection in Head and Neck Squamous Cell Carcinoma Patients. Annual Congress of the European Association of Nuclear Medicine, 2025.
7. Prognostic Utility of 18F-FDG PET/MRI with Intravoxel Incoherent Motion Imaging in Nasopharyngeal Carcinoma. Annual Congress of the European Association of Nuclear Medicine, 2025.